Exercise of Options, PDMR Dealing, EBT and TVR

CVS Group plc
09 October 2023
 

Immediate release                                                                                                                          9 October 2023

 

CVS Group Plc

("CVS", the "Company" or the "Group")

Exercise of Options, PDMR Dealing, EBT Share Purchase and Total Voting Rights

CVS, the UK listed veterinary group and a leading provider of veterinary services, announces that on 6 October 2023, options over a total of 107,903 new Ordinary shares of 0.2 pence each (the "New shares") were exercised under the CVS Group 2020 Long Term Incentive Plan ("LTIP 14"), at an exercise price of 0.2 pence. 

 

Richard Fairman, Chief Executive Officer, Ben Jacklin, Deputy CEO, and Robin Alfonso, Chief Financial Officer, exercised options over 41,030, 24,618 and 13,540 Ordinary shares of 0.2p each in the Company ("Ordinary shares") respectively.  The balance of the options was exercised by certain other employees of the Company.

 

On 6 October 2023, the Company was notified by JTC Employer Solutions Trustee Limited, the trustee of the CVS Group Employee Benefit Trust (the "EBT"), that the EBT had purchased a total of 56,896 of the New shares from LTIP 14 option-holders at a volume-weighted average price of £16.17 per Ordinary share.  This included the purchase of shares by the EBT from Richard Fairman, Ben Jacklin and Robin Alfonso to meet the costs of exercise incurred by them as PDMR option-holders, including personal taxation, as set out below:

 

Name                                    Number of shares sold to EBT                    Price

Richard Fairman                                19,510                                                   £16.17

Ben Jacklin                                          11,706                                                   £16.17

Robin Alfonso                                    6,439                                                     £16.17

 

 

The New shares purchased by the EBT are intended to be used to satisfy the exercise of share options by employees.  The EBT is a discretionary trust for the benefit of the Company's employees, including the Directors of the Company.  The purchase of the New shares by the EBT has been funded from the Company's existing cash reserves.  Following this transaction, a total of 57,280 Ordinary shares are held by the EBT, representing approximately 0.08% of the Company's total voting rights.

 

Admission of the New shares, which rank pari passu in all respects with the Company's existing Ordinary shares, has been satisfied by the Company's block listing admitted to the London Stock Exchange on 15 May 2023.

 

Following the issue of the New shares, the Company has a total issued share capital of 71,537,662 Ordinary shares each carrying one voting right.  The Company holds no Ordinary shares in treasury. Therefore, following the issue of the New shares, the total number of voting rights in the Company will be 71,537,662.  This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

 



 

Following their respective option exercises, their sales of a portion of the New shares arising and admission of the New shares, the Executive Directors, together with their respective spouses, hold a beneficial interest in the following Ordinary shares in the Company:

 

Name                                    Number of shares           Percentage interest in the Company

Richard Fairman                                77,501                                                   0.108%

Ben Jacklin                                          36,714                                                   0.051%

Robin Alfonso                                    19,252                                                   0.027%

 

The notification below, made in accordance with the requirements of the UK Market Abuse Regulation, provides further detail.

 

Contacts:

CVS Group plc                                                                                                                                via Camarco

Richard Fairman, CEO

Scott Morrison, Company Secretary

 

Peel Hunt LLP (Nominated Adviser & Broker)                                                 +44 (0)20 7418 8900

Adrian Trimmings / Michael Burke / Andrew Clark / Lalit Bose

 

   Berenberg (Joint Broker)                                                                                          +44 (0)20 3207 7800

Toby Flaux / Ben Wright / James Thompson / Milo Bonser

 

Camarco (Financial PR)                                                                                             

Geoffrey Pelham-Lane                                                                                +44 (0)7733 124 226

Ginny Pulbrook                                                                                                     +44 (0)7961 315 138

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

 

Richard Fairman

 

2

 

Reason for the notification

 

a)

 

Position/status

 

 

Chief Executive Officer

b)

 

Initial notification /Amendment

 

 

Initial Notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

 

CVS Group plc

b)

 

LEI

 

 

213800J41XDQ2NX48O05

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

 

a)

 

Description of the financial instrument, type of instrument

 

Identification code

 

 

Ordinary shares of 0.2 pence each

 

 

GB00B2863827

 

b)

 

Nature of the transaction

 

 

i)          Exercise of options under LTIP 14

ii)          Sale of Ordinary shares arising from exercise

c)

 

Price(s) and volume(s)

 

 

 

Price(s)

 

Volume(s)

i)    Exercise price of 0.2p

 

ii)    1616.5321p

41,030

19,510

 

 

d)

 

Aggregated information

 

- Aggregated volume

 

 

- Price

 

N/A

 

 

 

e)

 

Date of the transaction

 

 

6 October 2023

f)

 

Place of the transaction

 

 

i)          Outside a trading venue

ii)          London Stock Exchange, AIM.

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

 

Ben Jacklin

2

 

Reason for the notification

 

a)

 

Position/status

 

 

Deputy CEO

b)

 

Initial notification /Amendment

 

 

Initial Notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

 

CVS Group plc

b)

 

LEI

 

 

213800J41XDQ2NX48O05

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

 

a)

 

Description of the financial instrument, type of instrument

 

Identification code

 

 

Ordinary shares of 0.2 pence each

 

 

GB00B2863827

 

b)

 

Nature of the transaction

 

 

i)          Exercise of options under LTIP 14

ii)          Sale of Ordinary shares arising from exercise

c)

 

Price(s) and volume(s)

 

 

Price(s)

 

Volume(s)

i)    Exercise price of 0.2p

 

ii)    1616.5321p

24,618

11,706

 

 

d)

 

Aggregated information

 

- Aggregated volume

 

 

- Price

 

N/A

 

 

 

e)

 

Date of the transaction

 

 

6 October 2023

f)

 

Place of the transaction

 

 

i)          Outside a trading venue

ii)          London Stock Exchange, AIM.

 

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

 

Robin Alfonso

2

 

Reason for the notification

 

a)

 

Position/status

 

 

Chief Financial Officer

b)

 

Initial notification /Amendment

 

 

Initial Notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

 

CVS Group plc

b)

 

LEI

 

 

213800J41XDQ2NX48O05

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

 

a)

 

Description of the financial instrument, type of instrument

 

Identification code

 

 

Ordinary shares of 0.2 pence each

 

 

GB00B2863827

 

b)

 

Nature of the transaction

 

 

i)          Exercise of options under LTIP 14

ii)          Sale of Ordinary shares arising from exercise

c)

 

Price(s) and volume(s)

 

 

Price(s)

 

Volume(s)

i)    Exercise price of 0.2p

 

ii)    1616.5321p

13,540

6,439

 

 

d)

 

Aggregated information

 

- Aggregated volume

 

 

- Price

 

N/A

 

 

 

e)

 

Date of the transaction

 

 

6 October 2023

f)

 

Place of the transaction

 

 

i)          Outside a trading venue

ii)          London Stock Exchange, AIM.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 

Companies

CVS Group (CVSG)
UK 100

Latest directors dealings